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DMD #49593 Introduction
Although the use of medicinal herb, a principal component of traditional medicine, predates the emergence of HIV/AIDS, herbal products as immune boosters and for symptomatic management of AIDS have been popularized in Africa (Namuddu et al., 2011) . The high burden of HIV/AIDS has attracted various policy designs to accommodate a holistic approach to manage the scourge. While the crux of the various HIV/AIDS policies has been the introduction of free antiretroviral drugs (ARV), it is believed that the past controversy over HIV/AIDS and the official promotion of herbal medicine for its management have contributed to the persistently high rate of consumption of medicinal herbs by people living with DMD #49593 5 consumed among people living with HIV/AIDS in South Africa to boost immunity and enhance general well-being (Gericke, 2002) . It is referred to variously in local languages as insiswa, kankerbos, kankerbossie, , lerumo-lamadi, mukakana, phetola and unwele (Gericke et al, 2001 ). Its decoction is employed in the treatment of open wounds, fever, chicken pox, gastrointestinal cramps, rheumatism, heartburn, haemorrhoids, diabetes, inflammation and eye infections among indigenous South Africans (Van Wyk and Albrecht, 2008) . It has been investigated for many of the anecdotal claims. Many of such studies have suggested its potential for beneficial effects in HIV/AIDS (Harnett et al., 2005) , cancer (Stander et al., 2007; 2009; Skerman et al., 2011) , diabetis (Chadwick et al., 2007; Mackenzie et al., 2009; 2012) , inflammation (Ojewole, 2004) , microbial infection (Katerere and Eloff, 2005) , stress (Prevoo et al., 2004) and convulsion (Ojewole, 2008) . Commercial twice-daily Sutherlandia capsules containing 300mg powdered dried leaves are also available in the herbal medicines shops in South Africa (Van Wyk and Albrecht, 2008) .
DMD #49593
8 potassium dihydrogen phosphate (KH 2 PO 4 ) from Fluka Chemicals (Pty) Ltd (Buchs, Switzerland); 4'-hydroxydiclofenac from Calbiochem (Pty) Ltd (La Jolla, USA), (3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido [3,4-b] indole-3-propanoic acid 1,1-dimethylethyl ester (Ko143) from Tocris Bioscience (Pty) Ltd (Ellisville, MI); 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine-2 (PhIP) and its radio-labeled from (1.85 MBq/nmol, radiochemical purity >99%) from Toronto Research Chemicals (Pty) Ltd (North York, Canada); radio-labeled [ 
Assay enzymes and cells
Pooled mixed gender HLM prepared from 50 individual donors with total CYP and cytochrome b 5 content of 290 pmol/mg protein and 790 pmol/mg protein respectively was obtained from Gentest BD Biosciences (Woburn, USA). The Catalytic activities of enzymes were provided by the manufacturer. Pooled, mixed gender cryopreserved hepatocytes prepared from 20 donors were obtained from Celsis In Vitro technologies (Pty) Ltd (Baltimore, MD, USA), stored in a liquid nitrogen tank (until use), and thawed according to supplier instructions before use.
DMD #49593
henceforth referred to as ST was reconstituted in methanol and stored at -20ºC for further use.
Incubation in HLM
Thawed HLM were diluted with potassium phosphate buffer (50mM; pH = 7.4) and incubated in 96-well plate format. Graded concentrations of ST were prepared in methanol such that the addition of 1µL to 200µL incubation mixture yielded a final extract concentration of 0. 39, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50 and 100µg/mL respectively. Appropriate CYP substrate (table 1) was added and the mixture pre-incubated at 37°C for 10 minutes using an IS89 96-well plate incubator (Wesbart, Leimuiden, The Netherlands). Metabolic reactions were initiated by adding NADPH (1mM) and magnesium chloride (5mM) solution, and terminated after 20 minutes through the addition of formic acid (10 µL; 50%). All incubations were performed in duplicate. Control incubations contain CYP-specific inhibitor, and incubations without inhibitors. The final methanol concentration in the incubations was 0.5% (v/v). Probe substrate concentrations used were less or equal to published Km values.
Incubations in human liver microsomes for assessment of time-dependent inhibition
For the assessment of time-dependent inhibition of CYP3A4 activity, all incubation steps were performed in a 96-well plate format at 37°C using a liquid handling workstation epMotion 5075VAC (Eppendorf, Hamburg, Germany). ST (3.13, 6.25, 12.5, 25, 50 and 100 µg/mL) and positive control (5 µM troleandomycin) were added to phosphate buffer. After the addition of HLM (0.5mg/mL protein) and 10 min thermal equilibration, the reactions were initiated by adding NADPH (1mM). The samples were preincubated for 0, 4, 8, 16, 32 and 48 min respectively. All incubations were done in duplicate. After the preincubation period, 20 µL of the microsomal incubations (corresponding to 0.025 mg/mL protein) were diluted 20-fold with buffer containing the probe substrate and NADPH (in order to minimize competitive inhibition by the test compounds) and incubated with midazolam (20µM) for 6 minutes at 
Calculation of kinetic parameters for time-dependent inhibition
The enzyme activity in the presence of each inhibitor concentration was determined relative to activity at time t = 0. The resulting data pairs of relative enzyme activities and preincubation times were fitted with an Excel template in a least square approach to the exponential function (Equation 2) where y = relative activity; x = preincubation time; a = optimal starting value for relative activity; b = optimal negative rate of inactivation for a given inhibitor concentration
Equation 2
The rate of CYP3A4 inactivation in the absence of test substance was subtracted from all other inactivation rates. The resulting values along with the corresponding inhibitor concentrations were used in a second least square fit to calculate kinetic parameters by linear regression to the Michaelis-Menten-like equation (Equation 3) where y = inactivation rate constant; x = inhibitor concentration; KI = inhibitor concentration that produces half maximal inhibition; kinact = maximal inactivation rate constant employing the Enzyme Kinetic SigmaPlot Version 12.1.
The effects of ST on the clearance of midazolam in human hepatocytes
Incubation Procedure
The cryopreserved hepatocytes were thawed and the cells were suspended in HepatoZYME buffer. The viability of the suspended hepatocytes was determined at the beginning and end of incubation (in the presence and absence of ST by a Guava EasyCyte Mini system using the ViaCount assay according to the instructions of the supplier (Guava Technologies). After cell counting, the cell density was adjusted with HepatoZYME to approximately 1.3 million viable cells/mL. The incubation procedure involved the coincubation of 1 μM midazolam and 100 μg/mL ST in 1mL of hepatocyte mixture at 37°C under a humidified atmosphere of 95% air and 5% CO2 in a Heraeus incubator/Cytoperm. Aliquots of the incubation mixtures were taken for LC-MS analysis at 0, 1, 2, 4 and 6 hours of incubation. The metabolic reactions were stopped by the addition of 2 volumes of acetonitrile containing 0.3 M d4-hydroxymidazolam as internal standard. Samples were kept at -20°C until analysis. Control incubation to monitor the stability of midazolam in cell-free HepatoZYME was performed. The rate of metabolism of midazolam in the presence and absence of ST was compared. CLint in vitro = Lambda / cell density CLint in vivo = CLint in vitro x liver mass x heptocellularity From CLint in vivo and the hepatic blood flow (Q (20.7 mL/min)/kg body mass), the hepatic metabolic blood clearance (CLh,b) was predicted using the well-stirred model:
Clearance calculations
No corrections were made for the free fractions in vitro or in vivo i.e. they were assumed to be identical (Davies and Morris, 1993) . 
Determination of the effects of Sutherlandia on P-gp and BCRP
ST was soluble up to a final concentration of 700 µg/mL in P-gp uptake buffer and 200 µg/mL in BCRP uptake buffer. LLC-PK1 cells stably transfected with human P-gp were grown and maintained in Medium 199 supplemented with 10% FBS, 50 ng/µL Gentamycin and 100 ng/µL Hygromycin B at 37C under an atmosphere of 5% CO 2 . MDCKII cells stably transfected with human BCRP were grown and maintained in DMEM supplemented with 10% FBS, 1% L-Glutamine and 1% penicillin/streptomycin at 37C under an atmosphere of 5% CO 2 . Cells (~0.6 x 10 5 cells per well for LLC-PK1-P-gp and MDCKII-BCRP transfectants)
were seeded into Falcon ® clear bottom 96 well plates (Becton Dickinson) with 200 µL of culture medium and the assay was performed after 24 h. Graded concentrations of ST were prepared in HBSS containing 12.5 mM HEPES adjusted with HCL to pH 7.4 (for P-gp) and OPTIMEM containing 12.5mM HEPES adjusted to pH7.8 (for BCRP). The assay procedure was begun by the aspiration and replacing the culture medium with pre-incubation uptake buffer system containing ST or the specific inhibitors as positive control (10 µM cyclosporin A for P-gp and 1µM Ko143 for BCRP). Plates were subsequently incubated at 37C for 10 min.
Transporter-mediated uptake was initiated by the addition of the radiolabeled probe substrates (1µM digoxin for P-gp and 1µM PhIP for BCRP). The uptake reaction was terminated after 40 minutes by removing the incubation solution. The cells were then washed twice with ice-cold PBS buffer and monolayer integrity was assessed optically. This is followed by the dissolution of the cells by the addition on 0.2 N NaOH (200 µL per well) and incubation for 20 minutes at 37°C. Dissolved cells were then transferred to scintillation vials containing scintillation cocktail and uptake substrates were measured using a scintillation counter. All uptake studies were performed in triplicate in an incubator without shaking.
Methanol/DMSO was always below 1% v / v of the total volume and all solutions used in cell growth were maintained at the appropriate pH. were terminated after 5 minutes by removing the incubation solution. Subsequently, the wells were washed twice with ice-cold PBS buffer and monolayer integrity was assessed optically.
Radioactive samples were analyzed by liquid scintillation counting in a similar procedure as described above. All uptake studies were performed in triplicate in an incubator without shaking.
Drug uptake Clearance calculations
Probe substrate uptake clearance (nL/min/mg protein) by the stably transfected cells expressing the transporter proteins was determined from the specific amount of radiolabeled probe substrate inside the cells divided by the concentration in the incubation medium and normalized to the incubation time and the mean protein concentration measured in test wells.
This article has not been copyedited and formatted. The final version may differ from this version. The IC50 values (inhibitor concentration that causes 50% inhibition of the maximal drug effect) were calculated using the following equation:
Where, n is the slope factor (Hill coefficient), y0 is the relative baseline inhibition and a is the maximal transporter inhibition (%).
This article has not been copyedited and formatted. The final version may differ from this version. 
Results

Influence of ST on CYPs
ST showed a concentration-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A4/5. The extract concentration profiled against relative enzyme activity is shown in Figure 1 and Table 2 shows the IC 50 values. Little or no competitive inhibition of CYP2D6 and CYP2E1 was observed at ST concentrations up to 100 µg/mL.
Sutherlandia-induced time-dependent inhibition of CYP3A4
Time-dependent (irreversible) inhibition of CYP3A4/5 by graded concentration of ST was observed with a KI = 296 µg/mL and kinact = 0.063 min
) under the conditions of this study.
The influence of preincubation time, ST concentration and the positive control troleandomycin (TAO) on the enzymatic activity of CYP3A4/5 is illustrated in Figure 3 .
Influence of Sutherlandia on midazolam clearance in human hepatocytes
During the incubation with MDZ, the viability of the hepatocytes (percent viable cells relative to total cells) decreased from 78.3% at time zero to 42.7 without test inhibitor and 45.6 with ST. Thus, no cell degradation was attributable to the presence of ST.
Midazolam was also found to be stable in the HepatoZYME media and the absence of hepatocytes as determined after 6 hours of incubation. Thus, degradation in the presence of hepatocytes is attributable to the cellular activities.
Influence of Sutherlandia on the formation of midazolam metabolites
Following the analysis of an aliquot of human hepatocyte incubate with midazolam (t = 6h) by LC-MS/MS, four metabolites were detected and were assigned as M1, M2, M3 and M4. 
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However, a few factors may limit the conclusions derivable from this study. Sutherlandia was obtained from traditional healers, just as their clients do. The phytochemical composition of herbs is known to vary depending on the place and time of harvesting. In addition, methanol and water will extract most phytochemicals. This may not be the same with intestinal fluids.
The extracts that may be systemically available in significant quantities are also not known.
While in vitro HDI studies provide the indication for in vivo relevance, in vivo human studies are the ultimate proof of clinically significant HDI.
In conclusion, Sutherlandia may inhibit the metabolic clearance of co-medications Estimated GIT fluid = 250mL, with the assumption that the 60% methanol-soluble extracts are extracted in the GIT
